FDA Episodes
July 6, 2023
Home Health Hiccup + Rare Disease Priorities
Joanne Cunningham, CEO of the Partnership for Quality Home Healthcare, discusses the robust support for home health even as CMS aims to cut funding; Jeffrey Oldham, Director of State Government Relations and Advocacy for the Rare Access Action...
None
June 27, 2023
RSV Vaccines + Patient Experience Data
Ronda Miller-Ernest, a Pediatric Nurse Practitioner for more than 30 years, discusses the importance of RSV vaccines and the Vaccines for Children Program in the wake of an ACIP meeting; the FDA has opened up its public comment period for guidance...
None
May 23, 2023
Action Needed Against Alternative Funding Vendors
The House Energy and Commerce Health Subcommittee planned to markup 17 bills, but instead, the subcommittee only worked on six; Federal Trade Commission expands its probe into pharmacy benefit managers and group purchasing organizations; Carl Schmid,...
None
April 6, 2023
Discriminatory Health Metrics, Inclusive VA Healthcare
Neal Masia, Health Economist and Columbia University Professor of Business and Economics, discusses how the QALY discriminates against rare and chronic disease patients and calls for a more patient-focused health technology assessment; the Jax Act,...
None
April 4, 2023
Accelerated Approval Pathway for ALS Drug, Copay Accumulators Under Review
Rich Brennan, Vice President of Federal Affairs for the ALS Association, explains the approval pathway for Tofersen, a new ALS drug, and what that means for patients; Peter Pitts, President and co-founder of the Center for Medicine in the Public...
None